Quick Takeaways
- Deep Track Capital, LP filed SCHEDULE 13G/A for Nurix Therapeutics, Inc. Common Stock, par value $0.001 per share (NRIX).
- Disclosed ownership: 7.2%.
- Date of event: 31 Mar 2025.
Deep Track Capital, LP - 31 Mar 2025 SCHEDULE 13G/A Report for Nurix Therapeutics, Inc. Common Stock, par value $0.001 per share (NRIX)
- Filing Manager
- Deep Track Capital, LP
- Reporting Manager
- Deep Track Capital, LP
- Symbol
- NRIX
- Shares outstanding
- 76,282,940 shares
- Disclosed Ownership
- 5,500,000 shares
- Ownership
- 7.2%
- Form type
- SCHEDULE 13G/A
- Filing time
- 15 May 2025, 08:44:50 UTC
- Date of event
- 31 Mar 2025
- Previous filing
- 14 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Deep Track Capital, LP disclosed 7.2% ownership in Nurix Therapeutics, Inc. Common Stock, par value $0.001 per share (NRIX) on 31 Mar 2025."
What Changed
- Previous schedule filing date: 14 Feb 2025.
- Current filing was accepted on 15 May 2025, 08:44.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Deep Track Capital, LP | 7.2% | 5,500,000 | 0 | 5,500,000 | /s/ David Kroin | David Kroin, Managing Member of the General Partner of the Investment Adviser | |
| Deep Track Biotechnology Master Fund, Ltd. | 7.2% | 5,500,000 | 0 | 5,500,000 | /s/ David Kroin | David Kroin, Director | |
| David Kroin | 7.2% | 5,500,000 | 0 | 5,500,000 | /s/ David Kroin | David Kroin |